Liraglutide’s Future Uncertain: Panel Voices Concern Over Cancer And CV Risk
Executive Summary
Approval of Novo Nordisk's Victoza (liraglutide) for type 2 diabetes hinges on FDA's comfort with a safety database lacking on two fronts, an agency panel said April 2
You may also be interested in...
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
There is one message that sponsors should take to heart from an FDA advisory committee's first pass at applying new cardiovascular outcomes standards to type 2 diabetes medicines: enroll sicker patients in pivotal trials
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
There is one message that sponsors should take to heart from an FDA advisory committee's first pass at applying new cardiovascular outcomes standards to type 2 diabetes medicines: enroll sicker patients in pivotal trials
Liraglutide Cancer Signal Puts Agency In Uncharted Review Territory
Approving Novo Nordisk's Victoza (liraglutide) for type 2 diabetes would require FDA to surmount a substantial hurdle in the thyroid cancer signal seen with the GLP-1 analog